lab
repres
attract
altern
use
mucos
deliveri
system
liposom
microparticl
attenu
pathogen
box
review
discuss
potenti
medic
applic
recombin
dietari
lab
special
emphasi
lactococcu
lacti
lactobacillu
plantarum
speci
natur
inhabit
gastrointestin
tract
colon
oral
caviti
streptococcu
gordonii
nonlacticacidproduc
food
microorgan
staphylococcu
carnosu
staphylococcu
xylosu
bacillu
subtili
discuss
detail
review
describ
use
bacteria
mucos
deliveri
system
address
activ
research
pursu
develop
probioticbas
function
food
sever
articl
describ
lab
mucos
deliveri
vehicl
vivo
recent
publish
first
pilot
trial
recombin
lab
human
publish
ref
field
move
arena
human
clinic
trial
time
assess
learn
far
identifi
gap
understand
discuss
futur
potenti
lab
mucos
deliveri
vehicl
interest
use
lab
deliveri
vehicl
initi
focus
develop
mucos
vaccin
stem
larg
bodi
immunolog
research
show
deliveri
system
need
immunogen
degre
substanc
abil
evok
immun
respons
capac
produc
advers
reaction
avoid
degrad
promot
uptak
antigen
gastrointestin
tract
stimul
adapt
immun
respons
rather
tolerogen
immun
respons
seen
feed
studi
solubl
antigen
furthermor
success
use
attenu
bacteri
pathogen
vaccin
vector
heterolog
antigen
undoubtedli
influenti
set
import
preced
use
bacteria
deliveri
vehicl
although
pathogen
trait
facilit
entri
bacteri
vector
bodi
heighten
host
immun
respons
balanc
must
met
immunogen
versu
reactogen
lead
possibl
side
effect
decad
research
need
produc
vaccin
strain
attenu
salmonella
spp
maxim
immunogen
minim
side
effect
experiment
model
human
view
potenti
risk
revers
attenu
pathogen
wildtyp
virul
phenotyp
lab
repres
attract
altern
mucos
vaccin
carrier
one
major
advantag
lab
deliveri
vehicl
vaccin
potenti
elicit
antigenspecif
secretori
immunoglobulin
ig
respons
mucos
surfac
gener
accept
mucos
vaccin
elicit
secretori
iga
effect
system
immun
respons
could
advantag
mani
exist
vaccin
candid
lab
vaccin
elicit
antigenspecif
iga
respons
faec
saliva
bronchoalveolar
intestin
lavag
fluid
well
antigenspecif
igasecret
cell
lung
mesenter
lymph
node
tabl
studi
iga
respons
report
fluctuat
mice
seem
sustain
long
period
vaccin
howev
immunolog
memori
might
ensur
mucos
iga
respons
rapid
upon
subsequ
exposur
antigen
anoth
advantag
use
lab
mucos
deliveri
vehicl
engin
express
multipl
protein
molecul
exampl
express
type
capsul
biosynthesi
gene
streptococcu
pneumonia
l
lacti
produc
immunogen
serotyp
capsular
polysaccharid
main
entri
point
bacteria
particul
antigen
gener
thought
cell
locat
within
follicleassoci
epithelium
peyer
patch
possibl
smaller
isol
lymphoid
follicl
fig
howev
requir
peyer
patch
induct
activ
immun
oral
toler
still
controversi
bacteria
might
also
sampl
surfac
villu
epithelium
dendrit
cell
dc
penetr
epitheli
monolay
sampl
bacteria
lumin
side
littl
known
properti
lamina
propria
dc
might
traffic
mesenter
lymph
node
prime
tcell
respons
shown
dc
peyer
patch
fig
sampl
enterobact
cloaca
mous
commens
member
lab
dc
peyer
patch
recent
demonstr
follow
intragastr
challeng
x
coloni
form
unit
bacteria
express
green
fluoresc
protein
gfp
e
cloaca
recov
dc
wash
mesenter
lymph
node
hour
administr
viabl
bacteria
recov
splenocyt
system
tissu
intestin
dc
carri
small
number
viabl
e
cloaca
restrict
mucos
tissu
mesenter
lymph
node
suggest
result
tand
bcell
immun
respons
would
also
focus
box
advantag
lactic
acid
bacteria
mucosaldeliveri
vehicl
surviv
passag
stomach
acid
contact
bile
although
surviv
rate
straindepend
dietari
lactic
acid
bacteria
gra
gener
regard
safe
extens
use
ferment
food
product
mucos
rout
administr
potenti
stimul
system
mucos
immun
respons
elicit
product
secretori
immunoglobulin
fulfil
requir
deliveri
system
mucos
immun
taken
peyer
patch
induct
site
mucos
immun
system
kill
recombin
lactic
acid
bacteria
use
intranas
vaccin
induc
lowlevel
immun
respons
follow
mucos
administr
multipl
chimer
nonchimer
antigen
express
strain
engin
express
target
molecul
adjuv
lactic
acid
bacteria
lab
group
gramposit
nonsporul
bacteria
includ
speci
lactobacillu
leuconostoc
pediococcu
streptococcu
dietari
lab
refer
speci
strain
use
foodand
feedferment
process
term
lab
reflect
phylet
class
rather
group
organ
defin
abil
produc
common
end
product
lactic
acid
ferment
sugar
lab
limit
biosynthet
abil
requir
preform
amino
acid
b
vitamin
purin
pyrimidin
usual
sugar
carbon
energi
sourc
nutrit
requir
restrict
habitat
requir
compound
abund
nevertheless
lab
occupi
rang
nich
includ
milk
plant
surfac
oral
caviti
gastrointestin
tract
vagina
vertebr
compartment
respons
commens
bacteria
one
mechan
patholog
immun
respons
intestin
microbiota
avoid
also
impli
iga
respons
resid
commens
could
control
factor
uptak
bacteria
abil
lumin
bacteria
interact
system
immun
system
mucos
toler
nonpathogen
commens
lab
could
consid
benefici
properti
relat
mucos
deliveri
elimin
risk
provok
hypersensit
repeat
administr
relat
vaccin
use
howev
could
limit
potenti
elicit
effect
immun
respons
although
known
lab
vari
capac
surviv
passag
stomach
transient
persist
replic
human
gastrointestin
tract
isol
human
biopsi
definit
inform
fate
within
tissu
lack
recent
studi
human
biopsi
materi
colon
ileum
conclud
bacteria
present
mucu
layer
present
resid
lumin
side
furthermor
direct
contact
bacteria
epitheli
cell
observ
healthi
intestin
tissu
provid
surviv
transit
stomach
bacteria
introduc
intestin
tract
end
lumen
trap
mucu
layer
secret
goblet
cell
villiat
epithelium
small
intestin
nonvilli
epithelium
larg
bowel
shown
recombin
protein
secret
bacteria
releas
lyse
cell
could
come
contact
mucos
epithelium
step
polymer
immunoglobulin
iga
secret
matur
plasma
cell
lamina
propria
secret
via
polymer
iga
receptor
epitheli
cell
gut
lumen
could
potenti
control
factor
bacteri
persist
uptak
step
bacteria
contact
apic
surfac
epithelium
might
sampl
dendrit
cell
dc
pass
protrus
enterocyt
without
loss
epitheli
integr
step
heighten
inflamm
owe
chemotact
recruit
dc
could
also
occur
isol
lymphoid
follicl
found
colon
epithelium
peyer
patch
found
small
intestin
site
bacteria
particul
antigen
certain
cell
adhesin
gain
increas
access
special
follicularassoci
epithelium
overlay
mucos
lymphoid
follicl
cell
follicularassoci
epithelium
transport
lumin
antigen
across
epithelium
induc
primari
immun
respons
step
dc
present
dome
peyer
patch
phagocytos
bacteria
traffic
mesenter
lymph
node
directli
prime
tcell
respons
antigen
deriv
bacteria
step
epithelium
damag
exampl
result
acut
coliti
chronic
intestin
inflamm
lumin
bacteria
gain
access
epithelium
might
even
found
mucos
tissu
step
indic
commens
bacteria
present
either
suspens
lumen
trap
mucu
fig
would
howev
preclud
signal
host
via
solubl
factor
nonetheless
indic
repeat
oral
administr
certain
lab
might
promot
transient
persist
intim
contact
bacteria
epitheli
cell
approxim
peerreview
public
dealt
differ
aspect
develop
lab
vaccinedeliveri
vehicl
develop
express
system
lab
optim
antigengen
express
differ
cellular
locat
beyond
scope
articl
review
elsewher
follow
section
discuss
paramet
shown
influenc
immun
respons
lab
vaccin
bacteri
vehicl
choic
bacteri
vehicl
vaccin
deliveri
take
account
intrins
antigen
organ
sever
factor
could
affect
immunogen
systemat
investig
use
singl
model
antigen
tetanu
toxin
fragment
c
ttfc
antigen
express
three
differ
bacteri
host
l
lacti
lactobacillu
spp
gordonii
vari
respect
capac
surviv
persist
murin
gastrointestin
tract
oral
caviti
vagin
caviti
respect
use
mous
strain
recipi
strain
l
lacti
lactobacillu
spp
produc
ttfc
shown
independ
elicit
protect
immun
respons
challeng
tetanu
toxin
studi
directli
compar
differ
dosag
methodolog
recent
studi
compar
alanin
racemas
cellwal
mutant
l
lacti
l
plantarum
deliveri
vehicl
ttfc
conclud
l
plantarum
immunogen
l
lacti
approxim
tenfold
base
mean
serum
total
igg
titr
howev
studi
nisininduc
express
system
l
lacti
compar
strong
constitut
express
system
l
plantarum
possibl
nisin
treatment
affect
physiolog
surviv
l
lacti
gastrointestin
tract
direct
comparison
l
plantarum
lactobacillu
casei
l
lacti
use
repeat
bacteri
dose
immun
mice
intragastr
rout
found
overrid
advantag
use
lab
could
persist
elicit
antibodi
respons
ttfc
jw
mc
geoffroy
c
rush
unpublish
observ
although
three
bacteri
vector
differ
cellwal
composit
physiolog
behaviour
gastrointestin
tract
find
suggest
robust
persist
lab
vaccin
vector
factor
affect
induct
system
respons
express
antigen
lack
immun
respons
express
antigen
use
oral
rout
immun
report
least
two
publish
vaccin
studi
tabl
evid
literatur
unpublish
observ
indic
dose
requir
obtain
effici
prime
boost
antibodi
respons
via
intragastr
rout
via
intranas
rout
administr
preliminari
experi
intragastr
immun
compar
strain
l
lacti
express
differ
amount
ttfc
observ
antibodi
titr
higher
antigen
synthes
jw
k
robinson
unpublish
observ
thu
depend
immunogen
antigen
immun
regim
specif
threshold
amount
express
antigen
requir
elicit
immun
respons
might
exist
final
cellular
locat
express
foreign
antigen
cytoplasm
secret
anchor
cell
wall
also
anticip
influenc
immunogen
use
system
rout
administr
cytoplasm
cellwallanchor
mode
express
compar
ttfcexpress
l
lacti
provid
evid
antigen
locat
cell
surfac
immunogen
cytoplasm
antigen
contrast
use
mucos
rout
administr
intracellular
express
ttfc
immunogen
cellsurfac
express
antigen
human
papillomaviru
express
l
lacti
cytoplasm
secret
form
form
tether
cell
envelop
antigen
immunogen
evalu
measur
cellular
immun
respons
intranas
immun
mice
immun
cellwallanchor
antigen
elicit
higher
cytokin
respons
splenocyt
stimul
peptid
postimmun
immun
strain
express
intracellular
although
might
indic
cellwallanchor
form
antigen
immunogen
could
also
due
product
increas
total
amount
antigen
strain
express
cellwal
anchor
lowest
respons
obtain
strain
secret
anoth
immun
studi
carri
chicken
use
l
lacti
strain
express
infecti
bursal
diseas
viru
ibdv
capsid
protein
differ
cellular
locat
strain
immunogen
strain
nucleas
protein
fuse
cellwallanchor
domain
produc
signific
although
weak
igg
serum
respons
fact
cellwallanchor
strain
contain
antigen
attach
cell
wall
protoplast
fraction
therefor
rel
immunogen
could
due
increas
antigen
dose
locat
surfaceloc
antigen
might
suscept
degrad
highli
proteolyt
environ
digest
tract
nasopharyng
caviti
caution
need
extrapol
result
obtain
use
differ
rout
immun
thu
seem
best
locat
express
antigen
optim
mucos
immun
yet
conclus
identifi
addit
virtual
noth
known
de
novo
antigen
synthesi
effici
adjust
immun
respons
desir
level
tool
necessari
address
question
yet
develop
live
lab
use
deliveri
vehicl
replic
bacteria
de
novo
synthesi
antigen
influenc
immun
respons
intranas
immun
live
kill
l
lacti
use
formalin
mitomycin
c
express
ttfc
similar
level
antigenspecif
immunoglobulin
elicit
serum
separ
studi
l
lacti
strain
express
pneumococc
pspa
kill
strain
mitomycin
c
elicit
significantli
higher
pspaspecif
igg
titr
ratio
iga
titr
lung
use
live
vaccin
howev
inactiv
vaccin
reduc
efficaci
infecti
respiratori
challeng
attribut
reduct
helper
h
compon
immun
respons
similar
observ
made
use
recombin
strain
ttfcexpress
l
plantarum
seem
intranas
rout
although
vivo
synthesi
antigen
necessari
elicit
immun
respons
efficaci
vaccin
affect
depend
requir
immun
protect
h
versu
h
effect
kill
method
bacteri
vector
antigen
whether
nonrepl
lab
vaccin
would
effect
live
lab
oral
intragastr
rout
immun
influenti
kill
method
heat
gammairradi
remain
open
question
immun
respons
vaccin
antigen
ttfc
produc
inject
alum
adjuv
domin
h
respons
product
antibodi
wherea
mucos
deliveri
ttfcexpress
l
plantarum
l
lacti
induc
subclass
antibodi
ttfc
mous
model
gener
accept
h
cytokin
promot
class
switch
suppress
level
associ
h
immun
respons
thu
conclud
lab
vaccin
promot
mix
h
cell
respons
tabl
recent
confirm
analysi
cellular
respons
intragastr
intraperiton
administ
l
lactisexpress
ttfc
ttfcspecif
h
cell
respons
mix
h
h
cytokin
profil
found
intestin
spleen
follow
intragastr
immun
interestingli
howev
subclass
profil
obtain
lactococc
vaccin
administ
parenter
confirm
import
rout
vaccin
determin
respons
phenotyp
depend
target
organ
requir
immun
abil
lab
shift
cellular
immun
respons
toward
h
may
advantag
vaccin
strategi
recent
shown
respiratorychalleng
model
pneumococc
infect
clearli
bacteri
vehicl
influenc
immun
respons
understand
immunomodulatori
properti
differ
lab
continu
grow
possibl
select
strain
vaccin
applic
discuss
mani
probiot
organ
also
lab
box
better
character
capac
modul
immun
system
increas
knowledg
area
initi
studi
use
l
lacti
secret
biolog
activ
interleukin
il
ref
stimul
research
investig
whether
mucos
system
respons
could
enhanc
coexpress
secret
model
antigen
ttfc
compar
ttfcexpress
strain
peak
antittfc
serum
respons
higher
mice
immun
strain
also
express
fate
recombin
lactic
acid
bacteria
lab
mucos
bodi
caviti
oral
intranas
deliveri
immunogen
locat
express
antigen
intracellular
bacteri
cell
surfac
influenc
rout
administr
impact
bacteri
surviv
persist
vivo
replic
intens
induc
immun
respons
effect
intragastr
rout
depend
de
novo
synthesi
heterolog
molecul
bacteri
dosag
influenc
immunogen
lab
vaccin
would
repeat
dose
vaccin
strain
result
immunolog
toler
express
antigen
immun
respons
bacteri
vehicl
influenc
immunogen
express
antigen
vice
versa
induct
secretori
immunoglobulin
bacteri
carrier
influenc
vaccin
respons
capac
use
carrier
strain
repeat
vaccin
peyer
patch
necessari
induct
vaccin
respons
variou
bacteri
carrier
differ
uptak
cell
peyer
patch
entericco
formul
lab
protect
passag
stomach
owe
enter
coat
increas
efficaci
oral
vaccin
dose
requir
vaccin
larg
anim
lab
elicit
protect
respons
show
first
time
biolog
activ
cytokin
could
deliv
mucosa
use
lab
number
applic
sought
mucos
deliveri
use
recombin
l
lacti
effort
spur
part
side
effect
system
administr
pleiotrop
effect
b
cell
key
regul
h
differenti
interferong
produc
h
cell
play
crucial
part
stimul
naturalkillercel
activ
matur
cytotox
lymphocyt
thu
protect
infecti
diseas
vaccin
cancer
strain
l
lacti
coadminist
intranas
anoth
strain
l
lacti
express
cellwallanchor
antigen
main
aetiolog
agent
cervic
cancer
post
vaccin
mice
challeng
lethal
dose
tumour
cell
line
express
antigen
combinedvaccin
group
mice
protect
tumour
develop
least
day
compar
strain
l
lactisvaccin
group
control
group
respect
summari
amount
antigen
synthes
major
influenc
strength
induc
immun
respons
open
question
relat
immunogen
candid
bacteri
vector
box
includ
effect
rout
administr
locat
express
antigen
exampl
intracellular
secret
anchor
behaviour
bacteri
vector
vivo
includ
capac
direct
de
novo
antigen
synthesi
intranas
immun
seem
effici
intragastr
rout
elicit
system
respons
even
kill
organ
use
elicit
respons
rout
clear
transient
persist
bacteri
strain
advantag
vaccin
aspect
would
best
address
use
isogen
strain
engin
influenc
persist
vivo
evid
mucos
vaccin
use
l
lacti
l
plantarum
promot
mix
h
cell
respons
compar
inject
antigen
alum
understand
immunomodulatori
properti
differ
lab
increas
might
possibl
select
vaccin
carrier
influenc
balanc
h
h
product
infecti
challeng
studi
lab
vaccin
import
step
toward
applic
lab
vaccin
demonstr
protect
efficaci
anim
model
tabl
exampl
l
lacti
l
plantarum
vaccin
tetanu
capabl
elicit
signific
protect
lethal
challeng
dose
tetanu
toxin
furthermor
intranas
vaccin
lactococc
vaccin
express
conserv
crepeat
region
protein
pyogen
confer
signific
crossserotyp
protect
pharyng
infect
mice
vaccin
subcutan
protect
pharyng
infect
analysi
correl
antibodi
respons
protect
indic
antigenspecif
iga
respons
might
suffici
protect
vaccin
protect
erysipelothrix
rhusiopathia
swine
pathogen
report
use
mous
challeng
model
intragastr
intranas
immun
l
lacti
express
protect
antigen
spaa
oral
immun
l
lacti
express
env
protein
cell
surfac
shown
protect
effect
mice
challeng
intraperiton
vaccinia
viru
express
env
studi
howev
cholera
toxin
coadminist
l
lacti
mucos
adjuv
far
two
lab
vaccin
studi
measur
protect
infecti
challeng
compar
protect
afford
vaccin
purifi
antigen
deliv
adjuv
first
vaccin
studi
reveal
recombin
l
plantarum
strain
produc
ureas
b
antigen
elicit
partial
protect
helicobact
feli
mice
alanin
racemas
mutant
strain
superior
wild
type
reduc
load
h
feli
stomach
also
shown
use
ttfc
effect
vaccin
antigen
togeth
cholera
toxin
adjuv
reason
improv
vaccinedeliveri
properti
alanin
racemas
mutant
strain
unknown
howev
intestin
persist
wildtyp
mutant
strain
mice
similar
specul
might
due
enhanc
releas
antigen
vivo
second
studi
show
intranas
administr
l
lacti
express
pneumococc
surfac
protein
pspa
afford
better
protect
respiratori
challeng
virul
pneumococci
intranas
pspa
pspa
inject
alum
attribut
shift
toward
h
respons
sepsi
model
lactococc
vaccin
afford
protect
similar
obtain
inject
vaccin
decreas
colon
pneumonia
also
observ
mice
follow
nasal
inocul
differ
lab
express
pneumococc
surfac
antigen
although
success
vaccin
protect
achiev
use
lab
deliveri
vehicl
rodent
model
next
challeng
demonstr
efficaci
advantag
tradit
vaccin
anim
human
recent
develop
use
lab
deliveri
vehicl
field
dna
vaccin
advantag
dna
vaccin
lie
abil
induc
potent
cellular
immun
respons
addit
antibodi
express
multipl
antigen
epitop
use
one
dna
vector
viral
antigen
correct
posttransl
modif
exampl
glycosyl
carri
host
cell
machineri
howev
adapt
excel
result
achiev
small
anim
primat
larg
anim
beset
problem
use
attenu
enteroinvas
bacteria
dnavaccinedeliveri
vehicl
interest
owe
potenti
orallyadminist
vaccin
could
deliv
dna
directli
antigenpres
cell
immun
system
viral
promot
activ
sever
mammalian
cell
line
inflamm
larg
intestin
colon
refer
group
chronic
inflammatori
diseas
small
larg
intestin
main
form
crohn
diseas
ulcer
coliti
main
differ
crohn
diseas
ulcer
coliti
locat
natur
inflammatori
chang
crohn
diseas
affect
part
gastrointestin
tract
mouth
anu
although
case
start
termin
ileum
ulcer
coliti
contrast
restrict
colon
rectum
demonstr
sever
experiment
anim
model
attenu
intracellular
pathogen
salmonella
spp
listeria
monocytogen
shigella
flexneri
mycobacterium
bovi
mycobacterium
smegmati
abil
dna
vaccin
effect
prime
tcell
respons
depend
process
present
express
antigen
dc
mani
strategi
current
develop
target
dna
vaccin
cell
howev
dc
uptak
antigen
synthes
bystand
cell
could
also
contribut
natur
potenc
immun
respons
interestingli
recent
studi
show
recombin
l
lacti
express
internalin
surfac
protein
l
monocytogen
intern
epitheli
cell
vitro
enterocyt
vivo
administr
guinea
pig
furthermor
strain
carri
plasmidencod
gfp
control
cytomegaloviru
promot
p
cmv
gfp
express
observ
approxim
infect
cell
l
lacti
intrins
mechan
escap
endosom
phagosom
compart
remain
unclear
heterolog
dna
reach
nucleu
transcript
occur
subsequ
studi
deliveri
dna
mammalian
cell
demonstr
use
nativ
lactococci
contain
plasmidborn
bovin
blg
gene
control
viral
promot
p
cmv
function
l
lacti
synthesi
blg
observ
cell
incub
l
lacti
harbour
express
plasmid
incub
purifi
recombin
plasmid
alon
plasmid
mix
l
lacti
effici
deliveri
seem
low
clearli
potenti
optim
lab
dnavaccinedeliveri
vehicl
recent
immun
respons
l
acidophilu
carri
dna
vaccin
footandmouthdiseas
viru
investig
follow
administr
system
mucos
rout
signific
immun
respons
vaccin
antigen
detect
inject
rout
administr
although
mucos
administr
could
prime
specif
immun
respons
next
step
make
lab
effect
mucos
deliveri
vehicl
dna
vaccin
demonstr
immunogen
efficaci
anim
model
applic
recombin
lab
prevent
treatment
coliti
first
studi
use
l
lacti
two
differ
mous
model
interest
deliveri
therapi
coliti
stem
larg
bodi
scientif
literatur
show
cytokin
downregul
inflamm
affect
suffer
condit
review
ref
topic
enema
treatment
intraven
inject
clinic
benefit
daili
mucos
administr
l
lacti
caus
reduct
coliti
induc
dextran
sulphat
sodium
dss
prevent
onset
coliti
sv
ev
mice
spontan
develop
sever
coliti
benefici
effect
depend
secret
live
lactococci
situ
notabl
lower
dose
need
compar
intraven
inject
cytokin
apart
costeffect
approach
expect
mucos
deliveri
avoid
report
system
side
effect
associ
inject
address
safeti
concern
use
l
lacti
human
box
chromosom
thymidyl
synthas
thya
gene
replac
gene
gener
thymin
auxotroph
viabil
thya
strain
reduc
sever
order
magnitud
absenc
thymidin
thymin
contain
valid
vivo
pig
notabl
small
phase
trial
recent
conduct
thya
strain
patient
crohn
diseas
show
contain
strategi
effect
also
mucos
deliveri
l
lacti
feasibl
human
excit
landmark
studi
pave
way
develop
applic
human
potenti
use
lab
mucos
deliveri
peptid
trefoil
factor
famili
tff
also
investig
secretori
trefoil
peptid
well
known
potent
protect
heal
effect
mucos
damag
interest
potenti
therapeut
agent
inflammatori
bowel
diseas
howev
administ
oral
adher
mucu
small
intestin
thu
absorb
caecum
contrast
intragastr
administr
tffsecret
l
lacti
led
activ
deliveri
tff
peptid
mucosa
colon
clinic
report
drawn
attent
rare
isol
case
infect
lactobacillu
spp
usual
sever
immunocomprom
patient
genera
streptococci
contain
speci
recogn
opportunist
pathogen
although
strain
sensit
clinic
use
antibiot
although
lactic
acid
bacteria
lab
intrins
resist
antibiot
resist
trait
typic
mobil
horizont
gene
transfer
releas
genet
modifi
lab
pose
new
safeti
contain
issu
concern
includ
potenti
foreign
gene
affect
safeti
statu
lab
possibl
recombin
gene
product
could
unintent
effect
host
allergen
autoimmun
possibl
transgen
transgen
genet
modifi
organ
could
transfer
individu
propag
could
occur
outsid
host
also
import
issu
need
address
longterm
persist
unlik
concern
lab
persist
human
day
administr
thorough
evalu
safeti
issu
requir
casebycas
basi
strategi
adopt
contain
genet
modifi
l
lacti
express
human
might
also
suitabl
applic
futur
wallac
score
measur
rate
macroscop
lesion
one
ten
base
criteria
includ
inflamm
colon
thicken
hyperaemia
extent
ulcer
character
product
allergenspecif
ige
upon
exposur
allergen
induc
crosslink
highaffin
ige
receptor
mast
cell
basophil
releas
histamin
inflammatori
mediat
surround
tissu
develop
type
allergi
seem
reflect
imbal
tcellgovern
immun
particular
allergen
result
exagger
cytokin
respons
allergenspecif
ige
product
b
cell
effect
prevent
heal
acut
dssinduc
coliti
well
spontan
coliti
mous
model
inflammatori
bowel
diseas
new
strategi
treatment
coliti
recent
report
base
l
lactissecret
lcrv
antiinflammatori
protein
produc
pathogen
yersinia
evad
host
immun
respons
protect
therapeut
potenti
lcrvsecret
l
lacti
evalu
trinitrobenzen
sulphon
acid
tnb
dss
mous
model
coliti
tnbsinduc
coliti
model
protect
effect
l
lacti
secret
lcrv
approxim
base
macroscop
lesion
score
wallac
score
effici
strain
report
previous
lcrvsecret
l
lacti
strain
control
strain
also
effect
prevent
dssinduc
coliti
summari
recombin
lab
show
consider
potenti
mucos
therapi
inflammatori
bowel
diseas
human
prevent
therapi
type
allergi
allerg
asthmat
diseas
collect
known
atop
disord
affect
european
unit
state
popul
respons
substanti
healthcar
burden
societi
current
treatment
cure
allerg
diseas
allergenspecif
immunotherapi
patient
complianc
problem
howev
allergenspecif
immunotherapi
requir
repeat
administr
gradual
increas
amount
allergen
period
approxim
year
carri
inher
risk
allerg
reaction
treatment
mucos
deliveri
allergenexpress
lab
explor
approach
immunotherapi
type
allergi
base
find
strain
lab
modul
tcell
respons
express
coadminist
antigen
toward
h
immun
respons
concept
mucos
vaccin
type
allergi
offer
advantag
subcutan
rout
date
recombin
lab
shown
effect
strategi
prevent
allerg
sensit
mice
model
use
identifi
best
strain
allergenexpress
system
exampl
oral
pretreat
mice
l
lacti
strain
produc
cow
milk
allergen
blg
shown
partial
prevent
sensit
blg
foodhypersensit
mous
model
one
strain
produc
low
level
intracellular
blg
per
inoculum
x
lactococci
compar
strain
engin
secret
blg
per
inoculum
although
antigen
remain
mostli
cellassoci
pretreat
mice
strain
sensit
favour
develop
h
immun
respons
blg
significantli
decreas
level
blgspecif
ige
effect
strain
produc
highest
amount
blg
respect
inhal
allergen
modul
allerg
immun
respons
birchpollen
allergen
bet
recombin
lab
recent
describ
intranas
treatment
mice
recombin
lab
strain
express
bet
antigen
sensit
led
signific
shift
toward
nonallerg
h
immun
respons
bet
compar
nonexpress
control
strain
control
group
administ
buffer
intragastr
rout
seem
less
effect
modul
immun
respons
bet
recombin
l
plantarum
l
lacti
effect
rout
l
lacti
strain
produc
approxim
fourfold
less
bet
l
plantarum
strain
might
explain
lower
efficaci
strain
concur
previou
observ
reduct
blgspecif
ige
effect
l
lacti
strain
produc
highest
amount
allergen
howev
differ
two
strain
intrins
immunomodul
capac
andor
gut
persist
rule
contribut
factor
lab
deliveri
bet
also
induc
allergenspecif
iga
airway
gut
protect
capac
iga
respect
allergi
still
matter
gener
debat
mousemodel
studi
inhal
dustmit
allergen
der
shown
promis
result
use
oral
administ
recombin
lab
produc
der
reduc
local
allergeninduc
airway
inflamm
hyperreact
induct
oral
toler
chicken
ovalbumin
ova
also
report
intragastr
administr
l
lactissecret
ova
contrast
studi
mention
blg
bet
l
lacti
induc
counterregulatori
h
immun
respons
allergen
seem
ovaspecif
tcellreceptor
transgen
mice
oral
toler
mediat
induct
regulatori
cell
function
transforminggrowthfactor
mechan
remain
seen
whether
mechan
also
occur
nontransgen
mice
background
case
l
lacti
could
develop
effect
tool
induc
antigenspecif
toler
l
lacti
strain
discuss
intragastr
administ
consecut
day
sensit
blg
recent
shown
promot
oral
toler
young
mice
administr
l
lacti
secret
reduc
antigeninduc
anaphylaxi
almost
complet
inhibit
product
ige
antibodi
blg
interestingli
protect
effect
partli
attribut
l
lacti
wildtyp
strain
also
diminish
level
blgspecif
ige
moreov
result
studi
suggest
recombin
l
lacti
strain
increas
level
mucosa
promot
develop
antigenspecif
secretori
iga
addit
immunomodulatori
effect
lactococcaldeliv
investig
mous
model
ovainduc
asthma
blg
food
hypersensit
taken
togeth
studi
indic
futur
might
possibl
use
recombin
lab
induc
allergenspecif
toler
human
bioshield
strategi
work
neutral
immobil
virion
bacteria
must
inactiv
local
milieu
remov
host
reach
receptor
site
host
cell
date
research
focus
prevent
infect
mucosa
particular
method
use
women
protect
heterosexu
transmiss
cellbind
fusion
process
offer
number
potenti
target
site
inhibit
infect
fig
exampl
bind
extracellular
domain
immun
cell
first
step
viral
entri
block
highaffin
interact
microbicid
cyanovirinn
cvn
protein
highmannos
structur
present
ref
fig
first
human
commens
strain
lab
use
host
express
cvn
gordonii
cvn
express
fusion
protein
use
mprotein
secretionand
cellwallanchor
domain
sort
attach
cvn
cell
wall
form
recombin
gordonii
abl
captur
virion
vitro
cell
surfac
addit
cvn
secret
gordonii
bound
concentrationdepend
manner
l
lacti
l
plantarum
also
engin
express
high
level
cvn
optim
express
signal
translat
initi
secret
cvn
secret
strain
capabl
neutral
infect
laboratori
primari
isol
vitro
recent
natur
vagin
strain
lactobacillu
jensenii
engin
express
cvn
stabli
integr
express
cassett
recombin
genom
strain
capabl
colon
mous
vagina
produc
cvn
situ
protect
studi
use
strain
yet
publish
secret
two
extracellular
domain
human
vaginacolon
strain
l
jensenii
also
explor
strategi
antibodi
compris
variabl
region
heavi
light
chain
immunoglobulin
link
togeth
via
linker
peptid
express
surfac
lab
use
passiv
immunotherapi
exampl
shown
scfv
bind
major
adhes
molecul
streptococcu
mutan
caus
agent
dental
cari
protect
colon
tooth
enamel
dental
cari
agglutin
clearanc
bacterium
mouth
c
scfv
antibodi
express
surfac
lab
could
also
consid
immunotherapi
prophylaxi
exampl
scfv
might
prevent
pathogen
adher
neutral
lumin
bacteria
toxin
therebi
prevent
reach
epitheli
cell
introduct
exogen
antibodi
treat
diseas
prevent
infect
human
protein
reach
concentr
rang
ng
per
ml
laboratorycultur
supernat
inhibit
infect
cultur
cell
dosedepend
manner
similarli
l
casei
recent
use
secret
singlechain
fragment
variabl
scfv
antibodi
block
cellassoci
transmiss
across
vitro
cultur
model
cervic
epithelium
scfv
antibodi
specif
intercellular
adhes
molecul
thu
inhibit
bind
monocyt
activ
lymphocyt
epithelium
via
receptor
scfv
antibodi
secret
l
casei
shown
block
monocyteassoci
transmiss
across
cervic
epitheli
monolay
vitro
differ
approach
inhibit
cellfre
infect
use
peptidefus
inhibitor
deriv
carboxytermin
heptad
repeat
fig
exemplifi
recent
work
rao
colleagu
rather
use
lab
author
engin
probiot
strain
escherichia
coli
nissl
secret
peptid
recombin
strain
capabl
colon
mice
period
week
month
predominantli
colon
caecum
peptid
fusion
inhibitor
detect
throughout
mucos
lumen
epitheli
surfac
similarli
lactobacilli
express
fusioninhibitor
peptid
recent
experiment
evalu
potenti
bioshield
strategi
success
colon
lab
must
abl
compet
resid
microbiota
secret
suffici
quantiti
inhibitori
protein
block
infect
vivo
natur
occur
strain
lactobacillu
spp
introduc
vagina
prevent
vaginosi
report
persist
week
even
month
also
encourag
consid
cervicovagin
transmiss
men
women
ineffici
process
biologicalcontain
issu
surround
approach
certainli
need
address
necessari
biolog
contain
strain
limit
abil
surviv
outsid
laboratori
could
construct
use
human
although
might
impact
longev
efficaci
intervent
antiinfect
strategi
involv
recombin
lab
use
secret
cellsurfac
anchor
therapeut
neutral
antibodi
combat
pathogen
fig
c
one
strike
exampl
therapeut
approach
protect
experiment
vagin
shown
rat
use
gordonii
express
secret
surfacedisplay
microbicid
scfv
antibodi
candida
albican
fig
local
passiv
immunotherapi
dental
cari
also
achiev
use
strain
lactobacillu
zeae
display
scfv
form
antibodi
guy
direct
saiii
adhes
molecul
streptococcu
mutan
pathogen
involv
develop
dental
cari
fig
studi
recombin
l
zeae
administ
daili
owe
need
use
induc
promot
express
scfv
antibodi
futur
aim
use
strain
persist
continu
bind
entri
offer
sever
potenti
target
antivir
intervent
accord
latest
research
nativ
envelop
glycoprotein
cleav
form
subunit
direct
initi
interact
receptor
host
cell
stabil
structur
promot
bind
chemokin
receptor
mechan
trigger
conform
chang
fusion
peptid
enter
cellular
membran
initi
fusion
viral
envelop
cell
solubl
chemokin
neutral
antibodi
block
initi
bind
cell
receptor
format
fusion
intermedi
moreov
peptid
bind
expos
aminotermin
domain
thought
prevent
collaps
extend
trimer
structur
bring
aminoand
carboxytermin
region
close
proxim
promot
fusion
viral
cellular
membran
inhibitor
peptid
highli
conserv
differ
isol
one
current
clinic
use
conclus
futur
perspect
past
year
use
recombin
lab
mucos
deliveri
therapeut
prophylact
compound
well
dna
vaccin
increas
substanti
fig
despit
much
progress
gap
remain
understand
full
potenti
recombin
lab
mani
question
remain
unansw
exampl
littl
known
respons
elicit
nativ
antigen
lab
use
deliveri
vehicl
robinson
et
al
report
l
lacti
poorli
antigen
administ
vaccin
vector
via
intranas
intragastr
rout
although
significantli
elev
antibodi
titr
lab
measur
serum
immun
mice
compar
naiv
group
similarli
grangett
colleagu
observ
cellular
immun
respons
l
plantarum
even
lower
elicit
l
lacti
clearli
easier
obtain
immun
respons
intranas
administr
intragastr
administr
even
kill
lab
effect
rout
intranas
rout
immun
particularli
attract
elicit
last
antibodi
respons
system
airway
mucos
site
current
particular
interest
develop
airway
infect
pseudomona
aeruginosa
infect
patient
cystic
fibrosi
kill
lab
would
also
distinct
advantag
live
organ
respect
regulatori
issu
clinic
use
genet
modifi
organ
safeti
intranas
immun
lab
need
valid
although
immun
intragastr
administr
remain
attract
altern
mani
factor
suspect
impact
immun
respons
elicit
rout
remain
clarifi
base
protect
studi
perform
small
anim
difficult
predict
whether
necessari
dose
human
feasibl
econom
anticip
vaccin
studi
larger
anim
help
clarifi
issu
deliveri
dna
vaccin
use
lab
appeal
given
potenti
mucos
rout
administr
combin
effici
safe
deliveri
potenc
remain
major
futur
challeng
recombin
lab
also
show
promis
possibl
strategi
allergenspecif
immunotherapi
allerg
diseas
administr
antigenexpress
lab
sensit
antigen
shown
significantli
shift
immun
respons
toward
nonallerg
h
immun
respons
remain
seen
whether
secondari
prevent
treatment
lab
allergi
vaccin
would
inde
mitig
alreadyestablish
allerg
statu
recombin
lab
induc
antigenspecif
regulatori
cell
suggest
recent
studi
l
lacti
secret
ovalbumin
mucos
deliveri
relev
immunogen
could
also
effect
tool
treatment
antigeninduc
autoimmun
diseas
therapeut
applic
lab
progress
rapidli
past
year
follow
demonstr
lab
deliveri
could
treat
coliti
mous
model
small
phase
trial
recent
conduct
patient
crohn
diseas
develop
contain
system
genet
modifi
l
lacti
crucial
approv
clinic
studi
pave
way
labdeliveri
applic
futur
anoth
success
approach
prevent
treat
coliti
use
l
lacti
express
yersina
spp
lcrv
protein
stimul
mucos
synthesi
ref
novel
approach
highlight
potenti
use
immunomodul
protein
pathogen
novel
therapeut
excit
applic
horizon
concern
deliveri
antiinfect
scfv
antibodi
fusion
inhibitor
microbicid
prevent
infect
first
attempt
deliv
enzym
also
publish
includ
exampl
deliveri
lipas
correct
pancreat
defici
superoxid
dismutas
reduc
oxid
stress
possibl
coexpress
differ
factor
lab
antigen
enzym
scfv
antibodi
hosttarget
molecul
immunomodul
hope
applic
optim
biolog
contain
strain
develop
support
progress
toward
clinic
trial
sever
applic
lab
deliveri
seem
like
provid
clear
clinic
proof
near
futur
inflammatori
bowel
diseas
lab
deliveri
seem
realist
therapeut
option
human
illustr
publish
applic
lab
deliveri
variou
molecul
produc
lab
anim
model
use
type
molecul
singlechain
variabl
fragment
scfv
could
use
differ
applic
exampl
therapi
antiinfect
passiv
immun
potenti
applic
publish
literatur
date
